Article: Rabeprazole Delayed Release Tablets (Aciphex-Eisai Inc. and Janssen Pharmaceutic.

Pharmacology Update

Rabeprazole Delayed Release Tablets (AciphexEisai Inc. and Janssen Pharmaceutica)

By William T. Elliott, MD, FACP, and James Chan, PharmD, PhD

The fda has approved a third proton pump inhibitor (PPI) for the treatment of duodenal ulcers and gastroesophageal reflux disease (GERD). Rabeprazole (Aciphex) joins omeprazole (Prilosec) and lansoprazole (Prevacid) in this competitive, $3 billion worldwide market. Rabeprazole will be comarketed in this country by Eisai Inc and Janssen Pharmaceutica. The drug is a pyridyl methysulfinyl benzaminidazole, chemically similar to omeprazole. The PPIs inhibit gastric acid secretion by ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!